Heart Failure, Congestive Clinical Trial
Official title:
Heart Failure Evaluation Acute Referral Team Trial (HEARTT)
The purpose of this study is to assess the impact of a multidisciplinary team clinic including a clinical pharmacist, a registered nurse (RN), dietician and physician providing short-term sub-acute management of patients with heart failure on patient outcomes and the quality of medication use. Patients being discharged from the emergency department with a diagnosis of heart failure will be eligible for this study. We believe that emergency room visits, hospitalization and deaths secondary to heart failure will decrease secondary to this program.
BACKGROUND: Heart failure (HF)accounts for morbidity and mortality in Canada. In contrast to
coronary heart disease, the mortality rate attributed to HF has decreased minimally, only
14%, over the last 35 years. This is despite a plethora of new therapeutic modalities proven
to decrease mortality in HF. HF is also one of the leading causes of hospitalizations
accounting for the second highest total number of hospital days and the third highest number
of patients affected. It has been estimated that approximately 20-50% of patients will be
readmitted to hospital with one year. Patients seen in the emergency department (ED)and
discharged home from the ED are also at high risk for readmissions. A local study by our
group indicated that 44% of patients seen for HF in the ED have this disposition and as such
have a strikingly 50% higher readmission rate at 30 days compared to those admitted to
hospital. This difference could be explained by a "care gap" as evidence by a low
utilization of both angiotensin converting enzyme inhibitors and beta-blockers in this
group. However, a lack of patient education on self-care and follow-up post ED discharge
could also attribute to these rates. We propose testing a intervention employing a
multidisciplinary team to facilitate follow-up, provide HF education, including self-care,
and improve utilization of proven drug-therapy in patients discharged with HF from the ED on
the outcomes of hospitalizations and mortality.
PURPOSE: To improve the quality of care for patient with HF
HYPOTHESIS: Multidisciplinary team management of patients with HF has be shown to decrease
both morbidity and mortality in HF patients. A multifaceted program including rapid
referral, early short-term follow-up, medication initiation and titration and HF education
in collaboration with a dietician, nurse, pharmacist and physician will improve HF patient
care in terms of clinical outcomes, quality of life and evidence-based medication
utilization.
STUDY DESIGN: The study will utilize an unblinded randomized controlled trial (RCT) design.
Eligible patients will included patient discharged from the ED with a diagnosis of heart
failure. All patients referred from the ED will be seen in a rapid referral clinic within 1
week. Eligible patients will then randomized to an intervention arm or usual care. The usual
care group will have a consultation letter with recommendations sent their family doctor and
will receive a booklet on heart failure. The intervention arm will be followed in clinic
monthly by the multidisciplinary team. Medication will be initiated and titrated to target
dose. Patients will receive education regarding heart failure, medications, lifestyle, diet
and self-management. Communication will the patient's primary care provider will also be
enhanced.
SIGNIFICANCE: The literature describes a plethora of therapeutic modalities aimed at
improving the care of patients with HF. However, in terms of multifaceted disease management
interventions, the majority of HF studies have examined high risk patients that were
admitted to hospital or stable outpatients. This proposed study would examine a unique
population of patients being discharged from the emergency department.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |